Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Phekolo ea Schizophrenia: Teko e Ncha ea Clinical

ngotsoeng ke mohlophisi

MapLight Therapeutics e phatlalalitse hore e qalisitse teko ea bongaka ea Mokhahlelo oa 1 e hlahlobang ML-007, e leng mofuta oa kalafo o mocha o ntlafalitsoeng ho shebana le lipotoloho tse utloisisoang li sa sebetse hantle maemong a neurologic a kang schizophrenia le dyskinesias. Boithuto bo sa reroang, bo sa boneng, bo laoloang ke placebo bo tla lekola polokeho, mamello, le boemo ba pharmacokinetic ba ML-007 ho batho ba baholo ba phetseng hantle ba 58 ba lilemo tse 18 ho isa ho tse 45. Thuto e ntse e etsoa Canada 'me e tšehelitsoe ka lichelete ka botlalo. ka MapLight.

"Re thabetse ho kenya ML-007 tleliniking," ho boletse Christopher Kroeger, MD, MBA, Mookameli oa Phethahatso le Mothehi. "Re lumela hore phekolo ena e na le monyetla o moholo oa ho ntlafatsa bophelo ba bakuli ba nang le mathata a kelello a kang dyskinesias le schizophrenia."

ML-007 ke buka ea M1/M4 ea muscarinic agonist e sebetsang ho li-neurone ho basal ganglia. Ka ho sebelisa mochine o ikemetseng ho dopamine receptor, ML-007 e etselitsoe ho qoba liphello tse mpe tse amanang le liketso tse tobileng tsa dopamine receptor. Nyeoe e lebelletsoe ho phethela ho ingolisa kotareng ea pele ea 2022.

"Mekhoa ea phekolo e teng hona joale ha e sebetsane le litlhoko tsa bakuli ba nang le liphello tse fokolisang tsa dyskinesias le schizophrenia, 'me hangata li na le litla-morao tse ke keng tsa mamelloa," ho bolela MapLight Chief Medical Officer, Erin Pennock Foff, MD, Ph.D. "Phuputso ena e tla hlahisa lintlha tsa bohlokoa tse tla tsebisa nts'etsopele ea ML-007, 'me ke mohato oa pele o thabisang oa ho lekola bokhoni ba komporo ena."

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...